Concepedia

Ute Hoch

UH

54

Publications

3.4K

Citations

30

H-Index

1993

Active since

Affiliations

Nektar Therapeutics (United States)(Current)

The University of Texas MD Anderson Cancer Center

Sunesis (United States)

University of California, San Francisco

University of Würzburg

Ute Hoch is an author at Nektar Therapeutics (United States) specializing in medicine, biochemistry, and pharmacology.

ORCID

Top concepts

Publications per year

1993–2022

54

Publications

54

NKTR-214, an Engineered Cytokine with Biased IL2 Receptor Binding, Increased Tumor Exposure, and Marked Efficacy in Mouse Tumor Models

Deborah H. Charych, Ute Hoch, John L. Langowski et al. · Clinical Cancer Research · 2016 · 385 citations

Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah-Eddine Bentebibel et al. · Cancer Discovery · 2020 · 231 citations · Full text

A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors

Salah-Eddine Bentebibel, Michael E. Hurwitz, Chantale Bernatchez et al. · Cancer Discovery · 2019 · 228 citations

Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma

Wei-Gang Tong, Rong Chen, William Plunkett et al. · Journal of Clinical Oncology · 2010 · 215 citations

Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy

Meenu Sharma, Hiep Khong, Faisal Fa’ak et al. · Nature Communications · 2020 · 163 citations · Full text

Rows per page

1–5 of 54